scholarly journals Lifestyle Modifications as the first line therapy in Polycystic Ovary Syndrome

2015 ◽  
Vol 03 (01) ◽  
Author(s):  
Rajiv Mahendru ◽  
Saloni Bansal
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Lifestyle Modifications ◽  
First Line ◽  
Ovary Syndrome ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Update on polycystic ovary syndrome

2021 ◽  
Author(s):  
Jin Ju Kim
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Daily Practice ◽  
Antral Follicle ◽  
Reproductive Age ◽  
Lifestyle Modifications ◽  
First Line ◽  
Ovary Syndrome ◽  
Wide Range

Polycystic ovary syndrome (PCOS) is a common disorder in reproductive-age women. In 2018, an international evidence-based guideline announced recommendations spanning a wide range of issues on the assessment and management of PCOS. From the 166 recommendations, the present study reviews those that are of particular clinical relevance for daily practice and introduces other relevant studies that have been published since the global guideline. The 2018 guideline increased the antral follicle count cutoff for the diagnosis of PCOS from 12 to 20 when using a high-frequency probe. Hirsutism was defined as having a score of ≥4–6 based on a lower percentile of 85%–90% or cluster analysis, which was lower than the traditionally used 95th percentile-based cutoff. The diagnosis of PCOS in adolescents is challenging, and irregular menstruation was defined carefully according to years from menarche. The use of ultrasonography for the diagnosis of PCOS was restricted to those 8 years after menarche. As medication for non-fertility indications, combined oral contraceptives are the first-line drug. Metformin, in addition to lifestyle modifications, should be considered for adult patients with a body mass index ≥25 kg/m2 for the management of weight and metabolic outcomes. An aromatase inhibitor is the recommended first-line medication for ovulation induction, a subsequent individual patient data meta-analysis also reported the same conclusion. Whether the new global guideline will be fully adopted by many specialists and change clinical practice is open to question. Further studies are needed to better understand and manage PCOS patients well.

scholarly journals Effective treatment of skin and metabolic manifestations of hyperandrogenism: a comprehensive improvement of quality of life

2019 ◽  
pp. 45-50 ◽  
Author(s):  
V. E. Balan ◽  
Ya. Z. Zaydieva ◽  
E. V. Tikhomirova
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Clinical Manifestations ◽  
Adult Women ◽  
First Line ◽  
Timely Manner ◽  
Ovary Syndrome ◽  
First Line Therapy

Clinical manifestations of hyperandrogenism can be an important diagnostic symptom of polycystic ovary syndrome, and in most cases allow establishing this diagnosis in a timely manner. The article discusses the problem of acne not only in adolescence, but also in adult women, and the problem of hirsutism in detail. It shows the role of combined oral contraceptives (COCs) as an effective therapy for acne and hirsutism in women, as well as the first-line therapy for polycystic ovary syndrome, according to the international and national clinical guidelines. The data summarize the effectiveness of the use of COCs containing drospirenone as a gestagenic component and levomefolate calcium in order to compensate for folate deficiency and, accordingly, reduce the level of homocysteine, which is often elevated in women with hyperandrogenism.

Adherence To Lifestyle Modifications As A First-Line Therapy In Hypertension Management In Primary Health Care Setting, Medina, Saudi Arabia

2021 ◽  
Vol 9 (4) ◽  
pp. 1
Author(s):  
Abdulhadi Almadani ◽  
Abdulhameed Kashkari ◽  
Mohammed Almutairi ◽  
Mahmoud Alshanqiti ◽  
Obaid Aljarbou ◽  
...  
Keyword(s):  
Health Care ◽  
Saudi Arabia ◽  
Primary Health Care ◽  
Care Setting ◽  
Hypertension Management ◽  
Lifestyle Modifications ◽  
First Line ◽  
First Line Therapy ◽  
Primary Health ◽  
Line Therapy

scholarly journals A Review of First Line Infertility Treatments and Supporting Evidence in Women with Polycystic Ovary Syndrome

2019 ◽  
Vol 7 (9) ◽  
pp. 95 ◽  
Author(s):  
Michael Costello ◽  
Rhonda Garad ◽  
Roger Hart ◽  
Hayden Homer ◽  
Louise Johnson ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Multiple Pregnancy ◽  
Reproductive Age ◽  
Supporting Evidence ◽  
First Line ◽  
Ovary Syndrome ◽  
Ultrasound Monitoring

Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility in women of reproductive age. Lifestyle change is considered the first line treatment for the management of infertile anovulatory women with PCOS, and weight loss for those who are overweight or obese. First line medical ovulation induction therapy to improve fertility outcomes is letrozole, whilst other less efficacious ovulation induction agents, such as clomiphene citrate, metformin, and metformin combined with clomiphene citrate, may also be considered. Metformin combined with clomiphene citrate is more effective than clomiphene citrate alone. In obese women with PCOS, clomiphene citrate could be used in preference to metformin alone whilst clomiphene citrate could be added to metformin alone in order to improve reproductive outcome in all women with PCOS. Gonadotrophins, which are more effective than clomiphene citrate in therapy naïve women with PCOS, can be considered a first line therapy in the presence of ultrasound monitoring, following counselling on the cost and the potential risk of multiple pregnancy.

Sign in / Sign up

Export Citation Format

Share Document